R
Ruth Duncan
Researcher at Cardiff University
Publications - 221
Citations - 26091
Ruth Duncan is an academic researcher from Cardiff University. The author has contributed to research in topics: N-(2-Hydroxypropyl) methacrylamide & Methacrylamide. The author has an hindex of 73, co-authored 221 publications receiving 24991 citations. Previous affiliations of Ruth Duncan include University of Greenwich & Keele University.
Papers
More filters
Journal ArticleDOI
Evaluation of the biological properties of soluble chitosan and chitosan microspheres
Begona Carreno-Gomez,Ruth Duncan +1 more
TL;DR: Cytotoxicity towards B16F10 cells and ability to lyse rat erythrocytes was concentration-dependent and varied according to the salt used and polymer molecular weight, and polymers of higher molecular weight of each type were most toxic.
Journal ArticleDOI
Endocytosis and intracellular trafficking as gateways for nanomedicine delivery: opportunities and challenges.
TL;DR: The endomembrane trafficking pathways are overviewed, the methods used to determine and quantitate the intracellular fate of nanomedicines are discussed, and the current status of lysosomotropic and endOSomotropic delivery is reviewed.
Journal ArticleDOI
Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation
Sunil Shaunak,Sharyn Thomas,Elisabetta Gianasi,Antony Godwin,Emma Jones,Ian Teo,Kamiar Mireskandari,Philip J. Luthert,Ruth Duncan,Steve Patterson,Peng T. Khaw,Steve Brocchini +11 more
TL;DR: It is concluded that synthetically engineered macromolecules such as the dendrimers described here can be tailored to have defined immuno-modulatory and antiangiogenic properties, and they can be used synergistically to prevent scar tissue formation.
Book ChapterDOI
Soluble synthetic polymers as potential drug carriers
Ruth Duncan,Jindřich Kopeček +1 more
TL;DR: The consequences of the attachment of pharmaceuticals to macromolecular carriers with special reference to endocytosis and lysosomotropic drug delivery are discussed together with possible clinical applications.
Journal ArticleDOI
Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer.
Leonard W. Seymour,D. R. Ferry,David J. Kerr,Daniel Rea,Maggie Whitlock,Richard Poyner,Christopher M Boivin,Stuart Hesslewood,Chris Twelves,Robert Blackie,Andreas G. Schätzlein,Duncan I. Jodrell,Donald Bissett,Hilary Calvert,Michael J. Lind,Adele Robbins,Sally Burtles,Ruth Duncan,Jim Cassidy +18 more
TL;DR: Results show 6/62 PR with limited side effects supporting the concept that polymer-bound therapeutics can have modified and improved anticancer activities and suggesting the approach should be explored further for breast cancer and NSCLC.